About Cytosolic phospholipase A2 delta
Cytosolic phospholipase A2 delta (PLA2G4D) is a protein
from Homo sapiens identified by UniProt accession
Q86XP0, 818 residues long.
MolForge cross-references it against 0 known binders and
19 disease associations.
Target properties
| Protein name | Cytosolic phospholipase A2 delta |
|---|
| UniProt accession | Q86XP0 |
|---|
| Gene | PLA2G4D |
|---|
| Organism | Homo sapiens |
|---|
| Length | 818 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86XP0-F1 | alphafold | PREDICTED | 90.86 | — |
Amino-acid sequence (818 residues)
MESLSPGGPP GHPYQGEAST CWQLTVRVLE ARNLRWADLL SEADPYVILQ LSTAPGMKFK TKTLTDTSHP VWNEAFRFLI QSQVKNVLEL SIYDEDSVTE DDICFKVLYD ISEVLPGKLL RKTFSQSPQG EEELDVEFLM EETSDRPENL ITNKVIVARE LSCLDVHLDS TGSTAVVADQ DKLELELVLK GSYEDTQTSF LGTASAFRFH YMAALETELS GRLRSSRSNG WNGDNSAGYL TVPLRPLTIG KEVTMDVPAP NAPGVRLQLK AEGCPEELAV HLGFNLCAEE QAFLSRRKQV VAKALKQALQ LDRDLQEDEV PVVGIMATGG GARAMTSLYG HLLALQKLGL LDCVTYFSGI SGSTWTMAHL YGDPEWSQRD LEGPIRYARE HLAKSKLEVF SPERLASYRR ELELRAEQGH PTTFVDLWAL VLESMLHGQV MDQKLSGQRA ALERGQNPLP LYLSLNVKEN NLETLDFKEW VEFSPYEVGF LKYGAFVPPE LFGSEFFMGR LMRRIPEPRI CFLEAIWSNI FSLNLLDAWY DLTSSGESWK QHIKDKTRSL EKEPLTTSGT SSRLEASWLQ PGTALAQAFK GFLTGRPLHQ RSPNFLQGLQ LHQDYCSHKD FSTWADYQLD SMPSQLTPKE PRLCLVDAAY FINTSSPSMF RPGRRLDLIL SFDYSLSAPF EALQQTELYC RARGLPFPRV EPSPQDQHQP RECHLFSDPA CPEAPILLHF PLVNASFKDH SAPGVQRSPA ELQGGQVDLT GATCPYTLSN MTYKEEDFER LLRLSDYNVQ TSQGAILQAL RTALKHRTLE ARPPRAQT
Explore Cytosolic phospholipase A2 delta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets